Su1715 SUBCUTANEOUS VEDOLIZUMAB – A REAL WORLD EXPERIENCE
Edmond P. Morrissey, Jane McCarthy(Mercy University Hospital), Subrata Ghosh(University College Cork), Carthage Moran(University College Cork), Sarah Gleeson(Mercy University Hospital), Caitriona O Sullivan(Mercy University Hospital), Rachel Varley, K Sugrue(Mercy University Hospital), Donal Sheehan(University of Vienna), Martin Buckley(Mercy University Hospital)
Cited by 0
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558
Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease
|Nature Communications|2020|291
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
|Gastroenterology|2018|253